PD-L1 IHC 22C3 pharmDx Assay

PD-L1 IHC 22C3 pharmDx Assay

PD-L1 IHC 22C3 pharmDx Assay

OncologyPalliative Care
A badge with ribbon in color black Point(s): 1 | An analog clock in color black 1 hour | A black calendar with white triangle in center that has a black exclamation point in the middle 29 Nov 2022 

Overview

PD-L1 IHC 22C3 pharmDx is an assay that detects PD-L1 and is used to identify cancer patients eligible for pembrolizumab therapy. This E-course will give an overview of PD-L1 testing and the assay.


CPD Reviewer:

Professor Dr Pathmanathan Rajadurai

Senior Consultant Pathologist

Subang Jaya Medical Centre

Malaysia


Who should participate:

             Oncologists

             Pathologists


Learning objectives:

PD-L1 testing

             To provide an overview of PD-1/ PD-L1 checkpoint inhibitors and the importance of PD-L1 testing

             To discuss the challenges of PD-L1 testing and implications of using LDTs versus IVDs

             To review the importance of personalised medicine and CDx


PD-L1 IHC 22C3 pharmDx assay

To provide an overview of PD-L1 IHC 22C3 pharmDx assay –

             Assay overview

             Scoring guidelines: TPS & CPS

             Approved indications

             Platforms: SK006 (Autostainer link) and GE006 (Dako Omnis)

             Assay validation


Education & training resources

To provide guidance on –

             Online education & training resources for using and interpreting PD-L1 IHC 22C3 pharmDx assay

             External quality assurance programs for PD-L1 testing in laboratories


NOTE:

Please read thoroughly & understand the module before attempting the assessment questions.


Terms and Conditions:

             Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point.

             MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points.


Sponsored by:


Agilent_Logo_RGB.png

Supported by:

logo CPathAMM.png